Semin Thromb Hemost 2005; 31(2): 247
DOI: 10.1055/s-2005-869529

Copyright © 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel: +1(212) 584-4662.

Monitoring the New Antithrombotic Drugs

Jeanine M. Walenga, Debra A. Hoppensteadt
  • 1Departments of Thoracic and Cardiovascular Surgery and Pathology, Loyola University Medical Center, Maywood, Illinois
Further Information

Publication History

Publication Date:
26 April 2005 (online)

In the above-mentioned article, published in Seminars in Thrombosis and Hemostasis 2004; Volume 30, Number 6, Fig. [10] on page 692 is incorrect. The curves in the figure are mislabeled and should be interchanged such that fondaparinux is represented by the box and DX-9065a by the ellipse. The correct figure is given below.

Figure 10 Factor Xa inhibitors have varying responses in the clot-based anti-factor Xa assay (Heptest, Haemachem). The heparin pentasaccharide fondaparinux produces a dose-dependent linear response, whereas the Heptest is insensitive to the direct inhibitor DX-9065a.

Jeanine. M Walenga

Cardiovascular Institute, Loyola University Medical Center

2160 S. First Avenue, Maywood, IL 60153